secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001193125-23-247434
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 9.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb completes $2.5B acquisition of XIIDRA from Novartis, funded by $1.4B notes and $500M term loans
--------------------------------------------------------------------------------

- Acquired XIIDRA, libvatrep (Phase 2b), and AcuStream tech from Novartis for up to $2.5B ($1.75B upfront + $750M milestones).
- Funded with $1.4B of 8.375% senior secured notes due 2028 and $500M incremental term B loans.
- XIIDRA adds non-steroid dry eye treatment; combined with MIEBO, targets leading position in growing prescription DED market.
- Libvatrep Phase 2b study results expected H2 2023; AcuStream device aims at precise ophthalmic dosing.
- CEO Brent Saunders expects to 'quickly take a leading position in the growing prescription dry eye category.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523247434/0001193125-23-247434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523247434/d655401d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-247434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer